Flatiron, Foundation Medicine Tighten Integration for Genomic Test Ordering
Oncology practices can now order and track Foundation Medicine Inc.’s genomic profiling tests without leaving Flatiron Health’s OncoEMR platform, in the first of a series of integrations planned by Flatiron.
Cambridge, Mass.-based Foundation Medicine offers a suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.
New York City-based Flatiron offers oncology-specific EHR software, as well as the curation and development of real-world evidence for cancer research. In 2018 the global pharmaceutical company Roche acquired Flatiron in a deal worth $1.9 billion.
The companies said the new integration will support more efficient clinical decision-making by allowing electronic ordering, order tracking and receipt of Foundation Medicine’s CGP test results all within the OncoEMR platform.
“The integration of Foundation Medicine tests into OncoEMR, and other leading EMR systems to follow, is just one way we’re improving our offerings to fuel precision medicine for cancer patients. The integrations will create efficiencies for oncology healthcare teams to deliver precision treatment plans based on individual genomic insights to their patients,” said Kathleen Kaa, interim chief commercial officer at Foundation, in a statement.
“This kind of integration marks an important milestone in advancing precision medicine, helping oncologists have access to the information they need to select therapies,” said James Hamrick, M.D., M.P.H., vice president of clinical oncology at Flatiron Health, in a statement.
The two companies are planning similar integrations with other comprehensive genomic profiling platforms and EMRs, respectively, in the oncology space, with the goal of helping patients realize the benefit of precision cancer care. These workflow-streamlining integrations are being designed by clinical and product experts in partnership with oncology practices, they said.
